Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

BACKGROUND. The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Ellingson, Benjamin M., Harris, Robert J., Woodworth, Davis C., Leu, Kevin, Zaw, Okkar, Mason, Warren P., Sahebjam, Solmaz, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Lai, Albert, Nghiemphu, Phioanh L., Pope, Whitney B., Wen, Patrick Y., Cloughesy, Timothy F.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5193027/
https://ncbi.nlm.nih.gov/pubmed/27580889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now187
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items